Evidence map›Paper›PMID 34506257›Full record

ReviewHuman vaccines & immunotherapeutics2021

The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes.

Susan Yuill, Louiza S Velentzis, Megan Smith, Sam Egger, C David Wrede, Deborah Bateson, Marc Arbyn, Karen Canfell

Open access · bronzeAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Susan YuillDaffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0001-7609-972X
Louiza S VelentzisDaffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0002-9309-0492
Megan SmithDaffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0002-0401-2653
Sam EggerDaffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.
C David WredeDepartment of Oncology & Dysplasia, Royal Women's Hospital, Melbourne, Victoria, Australia.
Deborah BatesonFamily Planning NSW, Australia.ORCID 0000-0003-1035-7110
Marc ArbynUnit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.ORCID 0000-0001-7807-5908
Karen CanfellDaffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0002-6443-6618
The University of Sydney · AUGhent University · BERoyal Women's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the benefits of human papillomavirus (HPV) vaccination relating to cervical cancer prevention have been widely documented, recent published evidence is suggestive of an impact on adverse pregnancy outcomes (APOs) in vaccinated mothers and their infants, including a reduction in rates of preterm births and small for gestational age infants. In this review, we examine this evidence and the possible mechanisms by which HPV vaccination may prevent these APOs. Large-scale studies linking HPV vaccination status with birth registries are needed to confirm these results. Potential confounding factors to consider in future analyses include other risk factors for APOs, and historical changes in both the management of cervical precancerous lesions and prevention of APOs. If confirmed, these additional benefits of HPV vaccination in reducing APO rates will be of global significance, due to the substantial health, social and economic costs associated with APOs, strengthening the case for worldwide HPV immunization.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsFemaleHumansImmunizationInfant, NewbornPregnancyPregnancy OutcomeVaccinationPapillomavirus Vaccinesadverse pregnancy outcomesHPV vaccinationpreterm birthssmall for gestational age

Identifiers

PMID34506257
PMCPMC8437490
OpenAlexW3196653224

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.